A method and apparatus are provided for electrically stimulating muscle of individuals having little or no nerve damage so the muscle can be power contracted with little pain to the individual. A therapeutic current is applied to the muscle which includes alternating desensitizing and stimulus currents. The desensitizing current is a high frequency, low amplitude current to desensitize the muscle and the stimulus current is a low frequency, high amplitude current to stimulate the muscle. The currents alternate at a point where the amplitude and slope of the two currents are substantially identical to avoid abruptions in the current. An onset failure monitor circuit is also provided to detect an increase in skim/electrode impedance indicative of possible subsequent failure of the skin-electrode connection or electrode failure.
RELATED APPLICATION
This application is a continuation-in-part of my U.S. patent application Ser. No. 07/349,856, filed May 10, 1989 of the same title. The disclosure of that application is incorporated herein by reference.
An electrical human skin treatment apparatus which comprises a housing within which is incorporated an electrical circuit. The housing includes a pair of terminals which are spaced apart. The user's hand must be in contact with one terminal with the other terminal to be in contact with the area of application such as the face or neck of the user. The electrical circuit includes a slow voltage current rise to minimize the possibility of electrical shock to the user. A switch is incorporated on the exterior of the housing to not only activate the apparatus, but also to select anaphoresis or cataphoresis.
An electrotherapy stimulation unit having a high voltage pulsed current (HVPC) electrotherapy stimulation device providing short duration low amperage high voltage constant charge HVPC pulses to a patient to reduce pain, and a neuromuscular stimulation (NMS) electrotherapy device providing constant current NMS pulses to a patient to re-educate and prevent atrophy of muscle tissue. The HVPC device has a voltage source and at least one HVPC output circuit having a coil, a switching device, and a holding capacitor. When the switching device is turned on, an increasing current is drawn through the coil. When the switching device is turned off, a voltage spike results across the coil, charging the holding capacitor. Thereafter, the charge dissipates into the patient. The HVPC device senses the voltage provided by the voltage source and calculates the period of time the switching device is turned on based upon the sensed voltage and the preselected peak voltage of the voltage spike. The HVPC device provides a train of HVPC pulses, each HVPC pulse comprising first and second voltage spikes. The HVPC device detects whether a patient is properly connected to the HVPC output of the output circuit. If the second voltage spike is larger than the first by a predetermined value, a patient is not connected to the HVPC output circuit, and the output circuit is disabled.
5048522 - Power muscle stimulator - Owned by Therapeutic Technologies, Inc. (Tampa, FL) [*] Notice:The portion of the term of this patent subsequent to March 5, 2008 has been disclaimed.
A method and apparatus are provided for electrically stimulating muscle of individuals having little or no nerve damage so the muscle can be power contracted with little pain to the individual. A therapeutic current is applied to the muscle which includes alternating desensitizing and stimulus currents. The desensitizing current is a high frequency, low amplitude current to desensitize the muscle and the stimulus current is a low frequency, high amplitude current to stimulate the muscle. The currents alternate at a point where the amplitude and slope of the two currents are substantially identical to avoid abruptions in the current. An onset failure monitor circuit is also provided to detect an increase in skim/electrode impedance indicative of possible subsequent failure of the skin-electrode connection or electrode failure.
Augmentation of electrical conduction and contractility by biphasic cardiac pacing. A first stimulation phase is administered to the muscle tissue. This first stimulation phase has a predefined polarity, amplitude and duration. A second stimulation phase is then administered to the muscle tissue. This second phase also has a predefined polarity, amplitude and duration. The two phases are applied sequentially. Contrary to current thought, anodal stimulation is first applied and followed by cathodal stimulation. In this fashion, pulse conduction through the cardiac muscle is improved together with an increase in contractility. The technique can also be applied to large muscle tissue stimulation other than cardiac muscle.
A desired effect is produced by therapeutically activating tissue at a first site within a patient's body and a corresponding undesired side effect is reduced by blocking activation of tissue or conduction of action potentials at a second site within the patient's body by applying high frequency stimulation and/or direct current pulses at or near the second site. Time-varying DC pulses may be used before or after a high frequency blocking signal. The high frequency stimulation may begin before and continue during the therapeutic activation. The high frequency stimulation may begin with a relatively low amplitude, and the amplitude may be gradually increased. The desired effect may be promotion of micturition or defecation and the undesired side effect may be sphincter contraction. The desired effect may be defibrillation of the patient's atria or defibrillation of the patient's ventricles, and the undesired side effect may be pain.